Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Stage IV Breast Cancer AJCC v6 and v7: early-phase trial registry
2 of 15 indexed Stage IV Breast Cancer AJCC v6 and v7 trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #1,140 of 28,707 conditions by registered trial count.
15 US clinical trials · 2 currently recruiting · #1,140 of 28,707 conditions by registered trial count
Stage IV Breast Cancer AJCC v6 and v7: 15 US clinical trials tracked, 2 recruiting.
Stage IV Breast Cancer AJCC v6 and v7 is the subject of 15 registered US clinical trials on ClinicalTrials.gov, 2 of them currently open to new participants. 2 are in Phase 3-4 (later-stage) and 12 in Phase 1-2 (earlier-stage). The most active sponsor is National Cancer Institute (NCI), running 8 of these trials.
Enrollment posture brief
Registry condition stage-iv-breast-cancer-ajcc-v6-and-v7
OPEN 2 | RECR 13% | LATE 2 | EARLY 12 | RANK #1140 | SPON 8
Volume-matched condition peers
Nearest open-share peer: Drug Addiction (13% recruiting · 15 trials)
Stage IV Breast Cancer AJCC v6 and v7 lists 2 open slots (13% of 15 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Stage IV Breast Cancer AJCC v6 and v7 on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Stage IV Breast Cancer AJCC v6 and v7 is recruiting below its size-band peers.
2 of 15 indexed trials (13.3%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Stage IV Breast Cancer AJCC v6 and v7 research.
National Cancer Institute (NCI) accounts for 8 of 15 trials (53.3%). 5 distinct sponsors appear on at least one study for this condition label.
-
Most Stage IV Breast Cancer AJCC v6 and v7 trials plan to enrol fewer than 100 people.
Median target enrolment is 54 among the 15 trials that report a genuine target (sentinel values excluded). 13 of those (86.7%) plan for fewer than 100 participants.
-
Stage IV Breast Cancer AJCC v6 and v7 research is mostly interventional.
14 interventional and 1 observational studies make up this index (93.3% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
15 total, page 1 of 1
S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity
SWOG Cancer Research Network
NCT03418961
A Vaccine (MV-s-NAP) for the Treatment of Patients With Invasive Metastatic Breast Cancer
Mayo Clinic
NCT04521764
FES PET/CT in Predicting Response in Patients With Newly Diagnosed Metastatic Breast Cancer Receiving Endocrine Therapy
National Cancer Institute (NCI)
NCT02398773
Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast Cancer
National Cancer Institute (NCI)
NCT02311933
Genetic Analysis in Blood and Tumor Samples From Patients With Advanced or Metastatic Estrogen Receptor Positive and HER2 Negative Breast Cancer Receiving Palbociclib and Endocrine Therapy
Mayo Clinic
NCT03281902
Z-Endoxifen Hydrochloride in Treating Patients With Metastatic or Locally Recurrent Estrogen Receptor-Positive Breast Cancer
National Cancer Institute (NCI)
NCT01327781
Pembrolizumab, Endocrine Therapy, and Palbociclib in Treating Postmenopausal Patients With Newly Diagnosed Metastatic Stage IV Estrogen Receptor Positive Breast Cancer
City of Hope Medical Center
NCT02778685
Veliparib and Carboplatin in Treating Patients With HER2-Negative Metastatic Breast Cancer
National Cancer Institute (NCI)
NCT01251874
Nab-Paclitaxel in Treating Older Patients With Locally Advanced or Metastatic Breast Cancer
City of Hope Medical Center
NCT01463072
Cyclophosphamide and Veliparib in Treating Patients With Locally Advanced or Metastatic Breast Cancer
National Cancer Institute (NCI)
NCT01351909
Serial FES PET/CT to Measure Hormone Expression in Patients Undergoing Endocrine Targeted Therapy
University of Washington
NCT04692103
Paclitaxel, Nab-paclitaxel, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or Stage IV Breast Cancer
National Cancer Institute (NCI)
NCT00785291
Azacitidine and Entinostat in Treating Patients With Advanced Breast Cancer
National Cancer Institute (NCI)
NCT01349959
Dinaciclib and Epirubicin Hydrochloride in Treating Patients With Metastatic Triple-Negative Breast Cancer
National Cancer Institute (NCI)
NCT01624441
Ribociclib and Aromatase Inhibitor in Treating Older Participants With Hormone Receptor Positive Metastatic Breast Cancer
City of Hope Medical Center
NCT03477396
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 5 |
| Phase 2 | 7 |
| Phase 3 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Stage IV Breast Cancer AJCC v6 and v7 records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Stage IV Breast Cancer AJCC v6 and v7 trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Stage IV Breast Cancer AJCC v6 and v7 page
15 registered trials, 2 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 2 Stage IV Breast Cancer AJCC v6 and v7 trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- National Cancer Institute (NCI) sponsors the most Stage IV Breast Cancer AJCC v6 and v7 trials on record, review their full trial history before evaluating a specific study. See National Cancer Institute (NCI)'s trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Stage IV Breast Cancer AJCC v6 and v7 condition card totals 15 registered trials; most-linked intervention Laboratory Biomarker Analysis; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.